AR078950A1 - Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales - Google Patents

Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales

Info

Publication number
AR078950A1
AR078950A1 ARP100104153A ARP100104153A AR078950A1 AR 078950 A1 AR078950 A1 AR 078950A1 AR P100104153 A ARP100104153 A AR P100104153A AR P100104153 A ARP100104153 A AR P100104153A AR 078950 A1 AR078950 A1 AR 078950A1
Authority
AR
Argentina
Prior art keywords
acid
cys
asp
glu
carboxylated
Prior art date
Application number
ARP100104153A
Other languages
English (en)
Spanish (es)
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of AR078950A1 publication Critical patent/AR078950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
ARP100104153A 2009-11-09 2010-11-09 Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales AR078950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
AR078950A1 true AR078950A1 (es) 2011-12-14

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104153A AR078950A1 (es) 2009-11-09 2010-11-09 Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales

Country Status (26)

Country Link
US (3) US20140179607A9 (enExample)
EP (1) EP2499154B1 (enExample)
JP (1) JP5913115B2 (enExample)
KR (1) KR20120115495A (enExample)
CN (1) CN102812038B (enExample)
AR (1) AR078950A1 (enExample)
AU (1) AU2010314866B2 (enExample)
BR (1) BR112012011730A2 (enExample)
CA (1) CA2779482A1 (enExample)
CL (1) CL2012001186A1 (enExample)
CO (1) CO6551683A2 (enExample)
CR (1) CR20120303A (enExample)
EA (1) EA022817B1 (enExample)
EC (1) ECSP12011962A (enExample)
ES (1) ES2620153T3 (enExample)
GE (1) GEP20166435B (enExample)
IL (1) IL219596A0 (enExample)
MX (2) MX350046B (enExample)
NZ (1) NZ599751A (enExample)
PH (1) PH12012500916B1 (enExample)
SG (1) SG10201407403UA (enExample)
TW (1) TWI482626B (enExample)
UA (1) UA114274C2 (enExample)
UY (2) UY33017A (enExample)
WO (1) WO2011057272A1 (enExample)
ZA (1) ZA201203342B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2370087A4 (en) * 2008-12-02 2013-08-28 Ironwood Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF LIQUID RETENTION DISEASES
PH12012500916B1 (en) 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EP2509992B1 (en) * 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155108A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for disorders using guanylate cyclase c agonists
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
HUE032237T2 (en) * 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
AU2014331812B2 (en) * 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ES2216004T3 (es) 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2001256315A1 (en) * 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MX2009013293A (es) * 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
PH12012500916B1 (en) * 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
WO2011156453A2 (en) 2010-06-09 2011-12-15 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
UY33017A (es) 2011-06-30
CO6551683A2 (es) 2012-10-31
MX2012005368A (es) 2012-06-13
US20130085107A1 (en) 2013-04-04
ES2620153T3 (es) 2017-06-27
WO2011057272A1 (en) 2011-05-12
EP2499154B1 (en) 2016-12-21
UY33018A (es) 2011-01-31
AU2010314866B2 (en) 2014-10-30
ECSP12011962A (es) 2012-07-31
PH12012500916B1 (en) 2018-03-23
CN102812038B (zh) 2016-05-18
MX350046B (es) 2017-08-24
CR20120303A (es) 2012-08-08
EP2499154A1 (en) 2012-09-19
EA201290322A1 (ru) 2013-01-30
BR112012011730A2 (pt) 2016-03-08
GEP20166435B (en) 2016-02-25
US20110118184A1 (en) 2011-05-19
KR20120115495A (ko) 2012-10-18
US20140024593A1 (en) 2014-01-23
NZ599751A (en) 2014-08-29
JP2013510182A (ja) 2013-03-21
EA022817B1 (ru) 2016-03-31
JP5913115B2 (ja) 2016-05-11
SG10201407403UA (en) 2014-12-30
UA114274C2 (uk) 2017-05-25
PH12012500916A1 (en) 2018-01-29
TW201116291A (en) 2011-05-16
TWI482626B (zh) 2015-05-01
CA2779482A1 (en) 2011-05-12
US20140179607A9 (en) 2014-06-26
US8507447B2 (en) 2013-08-13
AU2010314866A1 (en) 2012-05-31
CL2012001186A1 (es) 2013-07-12
US8946158B2 (en) 2015-02-03
ZA201203342B (en) 2013-01-30
CN102812038A (zh) 2012-12-05
IL219596A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NZ599751A (en) Treatments for gastrointestinal disorders
Mercer et al. Peptides as the next generation of anti-infectives
CY1124910T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
MX2019013628A (es) Formulaciones que contienen linaclotida para administracion oral.
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
AU2018205186B2 (en) Angiotensin in treating brain conditions
MX2020001395A (es) Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.
CA2697504A1 (en) Salicylanilide modified peptides for use as oral therapeutics
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
WO2020028439A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
CA2839677A1 (en) Analogs of c5a and methods of using same
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
CA2748340A1 (en) .beta.-arrestin effectors and compositions and methods of use thereof
CA3073062A1 (en) Tau aggregation peptide inhibitors
RU2013146690A (ru) Циклические пептиды с антинеопластической и антиангионенной активностью
JP2020038211A (ja) 眼の感染症および疾患を処置するための組成物および方法
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
AR071774A1 (es) Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.
CA2912635A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
JP2016522178A (ja) 筋ジストロフィーにおけるアンジオテンシン
CA2940751A1 (en) Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke
US20090062212A1 (en) Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2
AR087727A1 (es) Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure